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5Chairman and CEO: 
overview and outlook
Ireland is encountering the most dynamic and challenging times 
in its economic history. Great change and transformation is already 
being experienced, and is inevitable for the foreseeable future. 
As a result, innovations in Ireland’s health system will be necessary 
if we are to improve effectiveness, efficiency and quality, and 
reduce costs. 
The development of new health-related products and services will also be essential 
for economic growth. The HRB, in applying health research and information to policy 
and practice, can play a substantial role in helping to secure Ireland’s economic future 
by improving health outcomes, driving health system innovation and enabling new 
enterprise opportunities. 
The HRB developed a new strategic business plan during 2009. This provides a clear 
strategic direction and specific objectives to develop Irish health research over the next 
five years. It focuses on improving health, transforming the way care is delivered and 
ensuring that good information and new knowledge are turned into practical benefits 
for policy and practice. The HRB strategic business plan was developed in parallel 
with the national Action Plan for Health Research in order to ensure that our actions 
are integrated into a co-ordinated approach to health research that is directly linked to 
national objectives.
The agenda-driven approach outlined in these plans will see us gradually concentrate 
our funding on research that offers the most potential for translation into impacts 
on, and benefits for, people’s health. It proposes to drive the development of the 
capacity, infrastructure and coherence of clinical, including applied biomedical 
research, population health sciences and health services research within our health 
6system. These are all research areas which need to be developed in order for funding 
investments in other areas, such as basic biomedical research to be realised; none of 
the areas receive significant funding from any other agencies.
This focus has involved making priority choices, and has resulted in a shift away 
from funding basic biomedical research. However, we firmly believe that funding 
basic biomedical research in Ireland is essential, and must continue. Within the 
current national structural arrangements for health and life sciences research, other 
agencies have a mandate to provide funding in this area and, in the current economic 
environment, our approach avoids unnecessary duplication. The key to optimising 
the State’s investment in health-related research, and to meeting the various sectoral 
requirements across the whole spectrum of health research, is to ensure that there is 
interactive collaboration between the different mission-led agencies. HRB is committed 
to, and is actively pursuing, such co-operation and collaboration.
This report outlines some examples of the impact that the HRB is having in terms 
of funding excellent research, building capacity within the research system, and 
generating information which will influence both policy and practice. At a glance, 
some of the main achievements in 2009 were: 
The development of an agenda-led strategic business plan that is both realistic • 
and workable. 
The completion of 111 grant awards which include impacts such as: • 
− eight patents and eight patent applications
− 18 new treatments and technologies
− 57 different types of evidence for policy and practice
− 85 new clinical trials
Restructuring and reshaping two of our main award schemes, the Health Research Awards • 
and Health Professional Fellowships, to reflect our new strategic direction.
The generation of information for decision-making among service planners, researchers • 
and policy makers, including: -
− the first ever national report on the social consequences of alcohol use 
− insight into the increasing future needs of people aged 50 and over with an 
intellectual disability
− the first Irish data on deaths among drug users from medical or traumatic causes 
− new information on the factors that influence GP attendance by people with 
mental health problems
7Significant progress made in developing clinical research facilities in three hospitals • 
in order to support clinical research capability in the wider health system.
The above examples do not reflect the full extent of work completed during the year. 
Staff have shown incredible focus and have delivered on challenging work programmes 
during a period of enormous change and we would like to acknowledge their 
commitment and hard work.
Board members have provided strong leadership throughout the year. They continue to 
provide the challenge that people need to push the boundaries of excellence, and they 
are supportive of new ideas that demonstrate initiative and make economic sense. We 
would like to acknowledge the contributions they have made all year and express our 
appreciation for their advice, direction and support.
Over the next few years, the challenges will be great for everyone in our economy and 
across the public service. However, we believe we can continue to deliver outcomes 
and impacts that can help transform our health services and support economic growth. 
This can be achieved through our new strategic focus, together with the Government’s 
commitment to invest in science, technology and innovation and the continued support 
of our stakeholders, particularly the Department of Health and Children and the Health 
Service Executive.
Dr Reg Shaw 
Chairman
Enda Connolly
Chief Executive
8Developing a new 
strategic direction 
Process and approach
In late 2008, the Chief Executive established a team to develop a strategic direction for 
health research for the the period 2010 - 2014. This initiative was driven by the need 
to address both the changing economic environment and a number of key issues and 
challenges including: 
major changes in the Irish health system • 
developments in the Irish research landscape over the previous decade • 
gaps in health research, clinical research leadership and capacity • 
the demand from academia and industry for access to the clinical environment • 
as research partners
an increased desire to focus on benefits, impact and value for money• 
The team worked closely with the HRB Board, key stakeholders and staff. They 
developed a clear vision and mission, and set an agenda of core goals to be pursued 
between 2010 and 2014. Central to the strategy is the aim of creating a coherent 
research system at the heart of our health service which executes and delivers 
quality research and information that can make an impact by improving people’s 
health, changing service delivery, brokering evidence into practice, and creating 
enterprise opportunities. This will involve achieving the highest quality of research 
and developing the right skills, conditions and capacity in the Irish health system to 
accelerate the translation of research discoveries into real benefits. 
Our vision: Healthy people through excellent research and applied knowledge. 
Our mission: To improve people’s health, patient care and health service delivery by:
leading and supporting excellent research by outstanding people within a coherent health • 
research system 
generating knowledge and promoting its application in policy and practice • 
and, as a result, play a key role in health system innovation and economic development.
9Our Goals: During the five-year period covered by this plan, we will focus on four 
strategic goals in order to achieve our vision and execute our mission:
1. Driving the development of excellent clinical research, including applied
biomedical research, within a coherent health research system. 
2. Building capacity to conduct high-quality population health sciences research
and health services research.
3. Working with key partners to develop and manage high-quality national
health information systems.
4. Generating and synthesising evidence, and promoting the application of knowledge 
to support decision-making by policy makers and relevant practitioners.
Engagement and consultation 
Central to the development of the plan were input, collaboration and engagement 
with a wide range of stakeholders. Contributions were provided by the Department 
of Health and Children; funding and development agencies in the realms of health, 
enterprise, education and science; the HSE, HIQA and a large number of health 
professionals and academics. This helped to ensure that the plan is well placed, not 
only to deliver better healthcare and services, but also to contribute to the wider 
agenda for economic development and further education. In consultation with these 
groups we mapped out the current landscape of research, information and funding, 
paying careful attention to ensure that the proposed areas of funding do not overlap or 
duplicate the work of other research funders.
The HRB strategic business plan was developed in parallel with the national Action Plan 
for Health Research 2009—2013 in order to ensure that our actions are integrated into a 
co-ordinated approach to health research that is directly linked to national objectives. 
Together these plans will see the HRB play a key leadership role in the further 
development of health research in Ireland. 
Designed to deliver
The new Health Research Board Strategic Business Plan 2010–2014 focuses on 
actions and has set out a range of key deliverables aimed at achieving the core goals. 
It commits the HRB to a number of overarching principles: 
a commitment to a culture of excellence in research and innovation• 
leadership of health research through partnership and collaboration• 
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a determination to have knowledge translated and applied• 
the commitment to having research at the core of the health system• 
a focus on good governance, high performance and value for money• 
A particular importance is placed not only on ensuring value for money, but on 
patient-oriented research and its application and translation into real benefits. There 
is also a strong emphasis placed on the need to develop our capacity to undertake 
population health science and health service research as key enablers of health service 
transformation. The strategic business plan commits us to optimising the use of current 
resources and to working in close collaboration with others, in order to achieve our 
vision of healthy people through excellent research and applied knowledge.
Some of the key actions in the plan include:
developing more patient-oriented research projects and programmes• 
increasing support for health services research and population health sciences• 
driving coherence and oversight within the health system • 
developing the research capacity of, and career paths for, our health professionals• 
establishing Clinical Research Facilities as an enabler of health research• 
creating health networks, centres and collaborative groupings of clinicians and other • 
health professionals
managing national health information systems that are fit for purpose and embedded in • 
the national information system framework
generating high-quality evidence that is adopted by policy makers and practitioners• 
leading innovative knowledge transfer initiatives that turn research evidence into policy • 
and practice
The Government has highlighted its on-going commitment to supporting research, 
development and innovation, despite the economic challenges facing the country. We 
fully recognise that the Government faces considerable constraints on the availability 
of finances for investment. This strategic business plan has been formulated in the full 
knowledge of these constraints and has reflected this in a number of ways.
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Health research: making an impact 
Each year the HRB reviews and evaluates the impact of funded research projects that 
have been completed during that year.
This section highlights how HRB-funded research is having an impact and is delivering 
outcomes in four key areas: 
developing new treatments, technologies and therapies • 
creating potential commercial opportunities and economic benefits• 
creating a robust research capacity and infrastructure • 
innovating health research reputation and healthcare policy and practice • 
It also provides some examples to illustrate the benefits resulting from HRB projects 
and programmes completed in 2009. 
Summary of outputs from projects and programmes completed during 2009
Output type 2009 2008 2007
Number of grants completed 111 93 55
Total number of research jobs supported through 
these grants
211 243 142
Total number of peer-reviewed publications published by 
people who received these awards
302 301 134
Commercial opportunities generated (e.g. patents) 21 N/A N/A
Additional funding leveraged by HRB–funded researchers 
on foot of their successful work, either on their own 
(direct) or within teams (indirect)
€70.7m N/A N/A
N/A means these figures were not collected previously 
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New treatments, technologies and therapies 
HRB-funded researchers are making a substantial contribution on the national and 
international stage by creating new therapies, technology, diagnostics and treatments. 
These successful discoveries are not only having an impact on people’s health, they 
are increasing Ireland’s capacity for enterprise and innovation. 
New treatment, technology and therapy outcomes from HRB–funded research in 
2009 included: 
1,628 patients•  were enrolled on cancer clinical trials (an increase of 600 since 2008).
Four • treatments for inoperable cancer, Epidermolysis Bullosa, MRSA and other 
antibacterial infections are in development.
Two diagnostic biomarkers•  for early detection of cardiovascular disease are 
in development.
Two • diagnostic imaging techniques are in train to improve epilepsy and optimise 
mammography examinations for detecting breast cancer.
The examples below further demonstrate our success in this area 
Clinical trial: 
 Most women with early stage breast cancer are advised to receive chemotherapy among other 
treatments. There is no evidence that chemotherapy benefits them all equally. In 2009, a total of 
340 Irish patients enrolled in a breast cancer clinical trial called TAILORx in 12 hospitals across 
Ireland. This study is looking at the women’s genetic profiles to find out if they would benefit 
from chemotherapy. Applied in practice, this could mean fewer women would need to undergo 
chemotherapy and suffer the related negative side effects. It would also reduce costs in the health 
system and save clinical time.
Online treatment success: 
 A team of HRB–funded researchers at University College Cork (UCC) found that a randomised 
control trial generated strong evidence that patients could successfully self-manage their 
warfarin treatment using an internet interface instead of having to attend traditional clinics. 
Patients involved in the trial were delighted with the freedom, as well as the convenience that 
this gave them.
New technology kills infections: 
 A study in Athlone Institute of Technology showed how a light and gas-based technology could 
be used to disinfect and sterilise medical instruments, devices and contact surfaces. While 
the technology has been employed successfully in the food industry, this is the first time that 
health–care infections such as MRSA have been tested. This light and gas-based technology 
has great potential to support infection control strategies in the future. 
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Creating potential commercial opportunities 
and economic benefits
Health research is by its nature patient-focused. However, increasingly, it is evident that 
health research has an incredible potential to generate commercial opportunities and 
develop the enterprise agenda. Our funded work also clearly illustrates a capacity to 
underpin changes in practice, which will generate significant cost savings across the 
health service. It also supports job creation and develops our knowledge economy. 
Many potential commercial opportunities and economic benefits may be derived from 
projects completed during 2009. Highlights include: 
eight patents were awarded and eight patent applications were submitted• 
85 new clinical trials were introduced • 
211 research jobs were supported• 
€70.7 million was leveraged from alternative funding sources• 
The examples below provide a snapshot of how this was achieved.
New business: 
 A new company being developed at University College Dublin (UCD) will license bioinformatics 
software (which applies statistics and computer science to molecular biology). The software was 
developed during the course of a HRB research grant.
New device: 
 A team at Cork Cancer Research Centre, UCC developed a new technology which will directly 
target cells in inoperable cancers. Clinical trials on this project will get underway shortly. 
Enterprise Ireland has provided funding to help bring the product to market.
Creating savings: 
 Another new innovation is StoppStart, a decision–support management tool for prescribing 
medicines which will have a major impact on patient safety. If implemented, at a cost of 
approximately €14 million in 50 hospitals, it has the potential to save around €180 million 
in unnecessary prescription costs as well as reduce other hospital costs.
Additional funding: 
 HRB principal investigators secured €14.7 million additional funding as a direct outcome of 
the success of their HRB–funded work. A further €56 million was secured by HRB grant holders 
through their participation on international research consortia.
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Developing research capacity and infrastructure 
In order to undertake high–quality research, develop world–class researchers and 
assimilate new advances from health research, it is essential to have the appropriate 
research infrastructure, culture and human capacity to innovate and embrace new 
knowledge. The HRB is committed to growing research capacity and infrastructure 
which supports people to undertake quality research, and the organisation plays a 
central role in developing a coherent approach to health research within our health 
system. This activity is incorporated into all of the HRB goals and objectives, and 
focuses on a number of important areas including: 
the development of careers and career paths for health professionals to include a • 
research dimension
the establishment of support infrastructure and facilities to enable world–class clinical • 
research and networks
the delivery of methodology support for researchers to stimulate robust research proposals• 
the cultivation of co-funding and collaborative arrangements to maximise research • 
opportunities
Some of our success in this area is reflected in the examples below.
Research career path for medical graduates: 
 In 2009, the HRB and the HSE continued to co-fund a fellowship scheme which enables 
medical graduates to undergo the specialist training required to attain consultant status while 
simultaneously carrying out research for a PhD, thereby ensuring that research is a 
core component of their clinical training.
Clinical Research Facilities progress: 
 The HRB funds three facilities, one in Dublin with the Wellcome Trust and one each in Galway 
and Cork. The creation of this infrastructure has resulted in: 
more than 800 patients being recruited to clinical studies in 2009 (600 in Dublin and 200 in Galway)• 
25 clinical research studies in diabetes, cancer, nephrology, dermatology, psychiatry, pulmonary • 
disease, neuropsychiatry and gastroenterology (four in Dublin and 21 in Galway) 
the creation of 15 full-time and four part-time jobs (11 in Dublin and eight in Galway)• 
the development of a clinical research programme in pharmabiotics and human nutrition, • 
cardiovascular disease and cancer (Cork)
Methodology support: 
 The HRB Centre for Support and Training in Analysis and Research (CSTAR) opened for business in 
September 2009. This two-year pilot project will provide statistical and methodological advice and 
support to strengthen quality in health services, primary care and clinical research. It also delivers 
training and education in research methodologies. There has been great demand for this support 
service. For more information visit their website: www.cstar.ie
Collaboration: 
 In 2009, the HRB co-funded research projects and programmes with the Health Service R&D Office 
in Northern Ireland, Wellcome Trust and the Irish Medical Charities Research Group. 
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Innovating healthcare policy and practice 
Many research studies provide compelling evidence for a need to make changes to 
policy and practice, but often these changes are not implemented, creating a ‘research 
-to-practice gap’. The HRB is committed to speeding up the translation of research 
discoveries into real benefits for health, and to closing the gap between research 
discovery and application in policy or practice. 
The growth of Ireland’s scientific reputation in health research also reinforces our 
ability to influence knowledge, policy and practice further afield.
During 2009 outcomes from 57 HRB projects had an impact on either policy or practice, 
and our funded researchers published in more than 300 international peer review 
journals.
Some examples are outlined below.
Change in practice: 
 One research fellow in the Royal College of Surgeons in Ireland (RCSI) demonstrated that 
repositioning patients with pressure ulcers at a 30 degree angle instead of a 90 degree angle 
reduced the incidence of pressure ulcers four-fold. This change in practice reduced the amount of 
time spent by nurses on dressing wounds, and saved money. It has now been adopted as an HSE 
best practice guideline.
Influencing policy: 
 Findings from a HRB–funded study on alcohol and unsafe sex conducted in the RCSI were quickly 
adopted by the HSE, Crisis Pregnancy Programme and others in reports and policy on alcohol-
related harm.
Improving diabetes outcomes: 
 One study in St Vincent’s University Hospital demonstrated that changing negative or ‘inaccurate’ 
perceptions among patients with poorly controlled type 2 diabetes could dramatically improve 
diabetes-related outcomes, such as blood sugar control and co-operation by using simple diet and 
exercise programmes.
Reducing tooth decay: 
 HRB–funded researchers in Cork University Dental School and Hospital produced comprehensive 
guidelines to reduce tooth decay in Irish children. The guidelines are practical, can be used in the 
existing health care services, and are focused on improving outcomes for patients.
High impact publications: 
 HRB researchers produced 302 peer-reviewed publications. 75% of these were published in 
prestigious international journals with medium-to high-impact factors. A journal’s impact factor 
reflects the number of citations it receives, indicating the prestige of the research published.
Coeliac gene discovery published: 
 A HRB-funded research team in the Institute of Molecular Medicine at St James’s Hospital 
discovered genes associated with coeliac disease as part of an international research group. 
The work was published in Nature and the New England Journal of Medicine.
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Funding research excellence
During 2009, the HRB awarded almost €29 million to new health research projects, 
bringing its total funding commitment across the Irish health research system to 
more than €193 million. This investment will help develop existing health research 
infrastructure and will underpin the development of research staff across Ireland’s 
health services; it will also ensure that the HRB’s research projects are of the highest 
quality, and will thus facilitate the delivery of improved health services and better 
health outcomes for people in Ireland. 
As in previous years, all investments were made on the basis of stringent international 
peer-review processes. Of the 1,069 applications received during the year, a total of 242 
were allocated funding support. A full breakdown of the funding awarded is set out below. 
This illustrates the number and variety of new health professionals, as well as details of the 
type of infrastructure projects and research programmes supported in 2009. 
Table 1 New awards made in 2009
No. of
Awards
Average 
award
investment
Total 
investment 
in scheme
Career support schemes and capacity building
Cochrane Fellowships 5 67,105 335,525
Summer Student Scholarship 47 2,000 94,000
NCI Summer Curriculum (Cancer Consortium) 18 2,000 35,000
Post-doctoral Research Fellowships 9 202,791 1,825,119
Health Professional Fellowships 16 171,891 2,750,258
Health Economics Fellowships 2 201,486 402,973
HRB/Marie Curie Post-doctoral Mobility Fellowships 3 261,842 785,526
National SpR/SR Academic Fellowships (NSAFP) 4 576,392 2,305,567
Research grants
Health Research Awards 42 212,000 8,888,299
HRB/MRCG co-funded awards 12 83,000 1,000,000
Training and workshops
Cochrane two-day course on systematic reviews 50 N/A N/A
Half-day ‘Introduction to Cochrane’ collaboration 128 N/A N/A
Infrastructure
ICORG hospitals and Group Central Office 12 350,000 12,600,000
Total 348 2,130,507 31,022,267
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The success rates on the two major HRB response-mode schemes, the Health 
Professional Fellowships and the Health Research Awards, are broadly in line with 
international norms (15-20%). The Health Research Awards, which were divided into 
five separate subjects areas, had an average success rate of 14%, while the Health 
Professional Fellowships success rate was 20.5%.
In line with the HRB Strategic Business Plan 2010–2014, the existing structure of the 
grant schemes was reviewed in 2009. This was to reflect the revised HRB research 
focus on areas which offer the most potential for translation into impacts and benefits 
for health policy and practice. As a result, from 2010 onwards, HRB funding awarded 
to projects, programmes and fellowships must now address patient-oriented research, 
health services research or population health sciences research.
For the Health Research Awards call, three new committees were proposed to underpin 
the strategic areas of:
Patient-oriented research • 
Population health sciences research• 
Health services research• 
Membership of committees, including Chairs, are drawn predominantly from 
outside Ireland.
For the Health Professional Fellowships, applications were sought from health professionals 
who are addressing research questions in one of the above strategic areas.
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Generating information
Sound evidence and high-quality information are central to good decision-making on 
health issues. 
The HRB manages five national information systems which provide the most up-to-date 
evidence for service planning and decision-making on issues such as alcohol and drug 
use, mental health and disability. The real benefit of these information systems is that 
they can provide epidemiological data fundamental to the health services and/or clear 
evidence about the areas where additional services are needed most. The information 
provided enables health service managers and policy-makers to make more effective 
decisions about services for the people who need them. A full list of the reports 
published by the HRB, or in journals, is set out in Appendix A. The full text of HRB 
reports is available on the HRB website: www.hrb.ie/publications.
The sample case studies outlined below illustrate the value generated from these 
information systems during 2009.
Trends and needs of over-50s with intellectual 
disability
The HRB undertook trend analysis on people aged 50 years and over who are 
registered on the National Intellectual Disability Database (NIDD). The findings 
showed that the demand for services for this age group is set to rise between 
2009 and 2014, as more people with an intellectual disability survive into older 
age. Therefore services will have to be developed to cater for this group.
Key findings
The number of people aged 50 years and over registered on the NIDD increased by • 
11%, from 3,869 in 2003 to 4,279 in 2007.
A positive shift away from the more traditional institutional settings and a move • 
towards community group homes. In 2003, 948 of this cohort were living in 
community group homes; the figure increased to 1,253 in 2007, a rise of almost 33%. 
Demand for multidisciplinary services such as psychiatry and medical services • 
appears to be influenced by age, with more people aged 65 years and over receiving 
these services.
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Social consequences of harmful alcohol use
Personal alcohol consumption is related to 60 medical conditions and leads 
to premature death from disease, accidents and injuries. In the first ever 
comprehensive Irish study on the wider social consequences of alcohol use, we 
revealed the extent of social problems; such as violence, public disturbance, 
poor work performance and family problems, which had never previously been 
quantified in Ireland.
The study shows that typical offender is a young male aged 24 years or under. 
Half of all offences are committed at weekends. Just under half of adult offences 
occur between midnight and 4.00am, with a peak at 2.00am.
Factors influencing attendance at the GP for 
mental health problems
This is the first survey to investigate the factors that influenced attendance 
at the GP, specifically for mental health problems. 
It showed that 12% of people on the island of Ireland were showing signs of 
significant psychological distress. Factors that influenced attendance at the GP were 
‘need’ factors such as mental health status, while ‘non-need’ factors such as income 
did not influence attendance. The report also highlights the important role of family 
and friends as a source of support for those experiencing psychological distress. 
The survey provides a baseline that can be used to monitor distress in Ireland and 
the associated health service use. It also identifies possible interventions to improve 
supports for mental health problems in the community and in primary care. 
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Deaths among drug users
This is the first Irish report to examine trends in deaths among drug users due to 
traumatic or medical causes, and not as a direct consequence of poisoning (overdose). 
The analysis showed that the number of deaths due to medical causes and trauma 
almost trebled between 1988 and 2005. In total there were 270 deaths due to medical 
causes, with the annual number rising from 11 in 1998 to 63 in 2005. 
The most common medical causes of death among drug users were cardiac events 
followed by respiratory infections and liver disease. Two-thirds of those who died 
from medical causes had a history of opiate use. Three in every five of those who 
died of liver disease had a history of alcohol dependence.
The number of deaths among drug users due to trauma doubled from 39 in 1988 
to 83 in 2005. Alcohol was present in almost two-thirds of cases. Cannabis, heroin 
and cocaine were found in the greatest proportions in deaths due to violence. 
Benzodiazepines and antidepressants were found in deaths involving hangings 
or drowning, which suggests that a portion of these cases may have had mental 
health problems.
Spina Bifida – HRB involved in research that 
eliminates suspected cause of the disease
The HRB played a key role in new research published in the New England Journal 
of Medicine in 2009 which shows that folic acid-related auto-antibodies are quite 
common throughout the Irish population, and that they are no more common in 
affected mothers than in other groups, including men. This refutes an earlier study 
that indicated a link between folic acid-related auto-antibodies in expectant women 
and the risk of neural tube defects in their babies.
The HRB worked with a team in Trinity College Dublin, the State University of New 
York and the National Institutes of Health in the US on the study. It involved 140 
mothers of affected children who were recruited through the Irish Association for 
Spina Bifida and Hydrochephalus, as well as an additional 238 Irish participants. 
It is the most definitive study to date to address the possible cause of Neural Tube 
Defects (NTDs). The finding is particularly relevant here in Ireland as we have one of 
the highest incidences of NTDs in the world, with one in every 1,000 babies affected. 
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Appendix A 
List of HRB publications
Alcohol and Drug Research Unit (2009) Drugnet Ireland. Issue 29, Spring. Dublin: Health Research Board.
Alcohol and Drug Research Unit (2009) Drugnet Ireland. Issue 30, Summer. Dublin: Health Research Board.
Alcohol and Drug Research Unit (2009) Drugnet Ireland. Issue 31, Autumn. Dublin: Health Research Board.
Alcohol and Drug Research Unit (2009) Drugnet Ireland. Issue 32, Winter. Dublin: Health Research Board.
Alcohol and Drug Research Unit (2009) 2008 National Report (2008 data) to the European Monitoring Committee 
on Drugs and Drug Addiction EMCDDA by the Reitox National Focal Point. Ireland: new developments, trends and 
in-depth information on selected issues. Dublin: Health Research Board. http://www.ndc.hrb.ie/toc.php?id=15
Daly A and Walsh D (2009) Activities of the Irish Psychiatric Units and Hospitals 2008. HRB Statistics Series 7. Dublin: 
Health Research Board.
Doyle A, O’Donovan M, and Craig S. (2009) National Physical and Sensory Disability Database Committee Annual 
Report 2008. HRB Statistics Series 7. Dublin: Health Research Board.
Kelly F, Kelly C, and Craig S (2009) Trends in demand for services among those aged 50 years and over with an 
intellectual disability, 2003-2007. HRB Trends Series 5, Dublin: HRB.
Kelly F, Kelly C, Maguire G and Craig S. (2009) Annual Report of the National Intellectual Disability Database 
Committee 2008, HRB Statistics Series 6, Dublin: Health Research Board.
Daly A (2008) National Psychiatric In-Patient Reporting System (NPIRS) Preliminary National Bulletin Ireland 2007. 
Dublin: Health Research Board.
Daly A (2009) National Psychiatric In-Patient Reporting System (NPIRS) HSE Dublin Mid-Leinster Bulletin 2008. 
Dublin: Health Research Board.
Daly A (2009) National Psychiatric In-Patient Reporting System (NPIRS) HSE Dublin North East Bulletin 2008. 
Dublin: Health Research Board.
Daly A (2009) National Psychiatric In-Patient Reporting System (NPIRS) HSE South Bulletin 2008. Dublin: Health 
Research Board.
Daly A (2009) National Psychiatric In-Patient Reporting System (NPIRS) HSE West Bulletin 2008. Dublin: Health 
Research Board.
Daly A (2009) National Psychiatric In-Patient Reporting System (NPIRS) National Bulletin Ireland 2008. Dublin: Health 
Research Board.
Lynn E, Lyons S, Walsh S and Long J (2009) Trends in deaths among drug users in Ireland from traumatic and 
medical causes, 1998 to 2005. HRB Trend Series 8. Dublin: Health Research Board.
Bellerose D, Carew A, Lyons S and Long J (2009) Trends in treated problem cocaine use in Ireland, 2002 to 2007. HRB 
Trend Series 6. Dublin: Health Research Board.
Carew A, Bellerose D, Lyons S and Long J (2009) Trends in treated problem opiate use in Ireland, 2002 to 2007. HRB 
Trend Series 7. Dublin: Health Research Board.
National Documentation Centre on Drug Use (2009) Directory of courses and training programmes on drug misuse in 
Ireland 2009. Dublin: Health Research Board.
Mongan D, Hope A and Nelson M (2009) Social consequences of harmful use of alcohol in Ireland. HRB Overview 
Series 9. Dublin: Health Research Board.
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O’Donovan M and Doyle A (2009) Measure of Activity and Participation (MAP): Participation and ageing: the 
experience of people on the NPSDD. MAP Bulletin No. 4. Dublin: Health Research Board.
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Appendix B 
Extract from the Financial Statements
Revenue Income and Expenditure Account
for the year ended 31 December 2009
2009 2008 
 €  € 
INCOME
Department of Health and Children revenue grant  35,241,000 36,884,529 
Other research funding 1,797,360 2,856,861 
Interest receivable  47,865  55,164 
Proceeds from insurance claim - 42,500 
Transfer to capital reserves of amount allocated 
to fund fixed assets
 (1,689)  -
 
 37,084,536 39,839,054 
EXPENDITURE
Research Strategy and Funding Directorate  30,052,265  32,886,411 
Health Information Systems and In-House Research 
Directorate
 3,987,247  3,942,935 
Corporate Function Directorate   3,027,062  3,138,340 
Pensions paid to retired members of staff  10,234           (135,169) 
 37,076,808  39,832,517 
SURPLUS FOR THE YEAR  7,728 6,537 
Revenue reserve at 1 January  49,197  42,660 
REVENUE RESERVES AT 31 DECEMBER  56,925  49,197 
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Capital Income and Expenditure Account
for the year ended 31 December 2009
 
2009 2008 
  €  € 
INCOME
Department of Health and Children capital grant 12,037,840 12,439,199 
Amortisation of capital fund account        87,617      155,578
Contribution to fund fixed assets            -     (158,683)
12,125,457 12,436,094
EXPENDITURE
Equipment grants and start-up funding         -      155,171 
Clinician Scientist Awards 2,555,363   2,479,348 
Imaging Awards    564,518   1,086,153 
Health Services R&D Awards 1,621,549   1,616,005 
PhD Scholars Programme 3,522,641   2,579,085 
Translational Research Awards 3,021,698   2,959,444 
Methodology Support Centre Award          -      599,330
Clinical Research Facilities     725,000      315,000 
Commissioned research          -      101,247 
ICT development          -      344,703 
Refurbishment costs       27,071        45,030 
Depreciation       84,944      116,240 
Loss on disposal of fixed assets         2,673        39,338 
12,125,457 12,436,094
(DEFICIT)/SURPLUS FOR THE YEAR              -            - 
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Balance Sheet
for the year ended 31 December 2009
2009 2008
  € €
FIXED ASSETS
Tangible assets    237,721     323,649 
CURRENT ASSETS
Debtors     549,483     436,933 
Investments            641           641 
Cash at bank and on hand     403,366           500 
   953,490     438,074 
CURRENT LIABILITIES
Amounts falling due within one year:
Bank           - 11,569 
Creditors 896,565 377,308 
896,565 388,877 
NET CURRENT ASSETS 56,925 49,197 
NET ASSETS 294,646 372,846
RESERVES
Accumulated surplus on 
income and expenditure account      56,925       49,197 
Capital fund    237,721     323,649 
   294,646     372,846 
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